390 related articles for article (PubMed ID: 22616948)
1. Thiazolidinedione safety.
Kung J; Henry RR
Expert Opin Drug Saf; 2012 Jul; 11(4):565-79. PubMed ID: 22616948
[TBL] [Abstract][Full Text] [Related]
2. Examining the safety of PPAR agonists - current trends and future prospects.
Bortolini M; Wright MB; Bopst M; Balas B
Expert Opin Drug Saf; 2013 Jan; 12(1):65-79. PubMed ID: 23134541
[TBL] [Abstract][Full Text] [Related]
3. The safety of thiazolidinediones.
Tolman KG
Expert Opin Drug Saf; 2011 May; 10(3):419-28. PubMed ID: 21366501
[TBL] [Abstract][Full Text] [Related]
4. Thiazolidinediones, peripheral oedema and congestive heart failure: what is the evidence?
Patel C; Wyne KL; McGuire DK
Diab Vasc Dis Res; 2005 May; 2(2):61-6. PubMed ID: 16305060
[TBL] [Abstract][Full Text] [Related]
5. Pleiotropic effects of thiazolidinediones: implications for the treatment of patients with type 2 diabetes mellitus.
Defronzo RA; Mehta RJ; Schnure JJ
Hosp Pract (1995); 2013 Apr; 41(2):132-47. PubMed ID: 23680744
[TBL] [Abstract][Full Text] [Related]
6. The current role of thiazolidinediones in diabetes management.
Rizos CV; Kei A; Elisaf MS
Arch Toxicol; 2016 Aug; 90(8):1861-81. PubMed ID: 27165418
[TBL] [Abstract][Full Text] [Related]
7. Thiazolidinedione insulin sensitizers and the heart: a tale of two organs?
Buckingham RE; Hanna A
Diabetes Obes Metab; 2008 Apr; 10(4):312-28. PubMed ID: 18333890
[TBL] [Abstract][Full Text] [Related]
8. Dual PPAR alpha/gamma agonists: promises and pitfalls in type 2 diabetes.
Ahmed I; Furlong K; Flood J; Treat VP; Goldstein BJ
Am J Ther; 2007; 14(1):49-62. PubMed ID: 17303976
[TBL] [Abstract][Full Text] [Related]
9. Thiazolidinediones in type 2 diabetes: a cardiology perspective.
Khanderia U; Pop-Busui R; Eagle KA
Ann Pharmacother; 2008 Oct; 42(10):1466-74. PubMed ID: 18698014
[TBL] [Abstract][Full Text] [Related]
10. PPAR agonists for the treatment of cardiovascular disease in patients with diabetes.
Wilding JP
Diabetes Obes Metab; 2012 Nov; 14(11):973-82. PubMed ID: 22443197
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic potential of aleglitazar, a new dual PPAR-α/γ agonist: implications for cardiovascular disease in patients with diabetes mellitus.
Cavender MA; Lincoff AM
Am J Cardiovasc Drugs; 2010; 10(4):209-16. PubMed ID: 20653327
[TBL] [Abstract][Full Text] [Related]
12. Cardiovascular, ocular and bone adverse reactions associated with thiazolidinediones: a disproportionality analysis of the US FDA adverse event reporting system database.
Motola D; Piccinni C; Biagi C; Raschi E; Marra A; Marchesini G; Poluzzi E
Drug Saf; 2012 Apr; 35(4):315-23. PubMed ID: 22376166
[TBL] [Abstract][Full Text] [Related]
13. Pioglitazone: side effect and safety profile.
Shah P; Mudaliar S
Expert Opin Drug Saf; 2010 Mar; 9(2):347-54. PubMed ID: 20175701
[TBL] [Abstract][Full Text] [Related]
14. Use of pioglitazone in the treatment of diabetes: effect on cardiovascular risk.
Zou C; Hu H
Vasc Health Risk Manag; 2013; 9():429-33. PubMed ID: 24023518
[TBL] [Abstract][Full Text] [Related]
15. Association between thiazolidinedione treatment and risk of macular edema among patients with type 2 diabetes.
Idris I; Warren G; Donnelly R
Arch Intern Med; 2012 Jul; 172(13):1005-11. PubMed ID: 22688528
[TBL] [Abstract][Full Text] [Related]
16. Sex-specific differences in Type 2 Diabetes Mellitus and dyslipidemia therapy: PPAR agonists.
Benz V; Kintscher U; Foryst-Ludwig A
Handb Exp Pharmacol; 2012; (214):387-410. PubMed ID: 23027460
[TBL] [Abstract][Full Text] [Related]
17. Thiazolidinedione-induced skeletal fragility--mechanisms and implications.
Grey A
Diabetes Obes Metab; 2009 Apr; 11(4):275-84. PubMed ID: 18671797
[TBL] [Abstract][Full Text] [Related]
18. [Heart failure with thiazolidinedione treatment: what do we know today?].
Erdmann E
Dtsch Med Wochenschr; 2009 Jan; 134(4):154-8. PubMed ID: 19148858
[TBL] [Abstract][Full Text] [Related]
19. Do thiazolidinediones still have a role in treatment of type 2 diabetes mellitus?
Consoli A; Formoso G
Diabetes Obes Metab; 2013 Nov; 15(11):967-77. PubMed ID: 23522285
[TBL] [Abstract][Full Text] [Related]
20. Does Thiazolidinedione therapy exacerbate fluid retention in congestive heart failure?
Goltsman I; Khoury EE; Winaver J; Abassi Z
Pharmacol Ther; 2016 Dec; 168():75-97. PubMed ID: 27598860
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
